PROGNOSIS OF UNCONTROLLED DIABETES AND HYPERTENSION LEADS TO SECONDARY COMPLICATIONS: A CASE REPORT
Huma Naeem, Ashfaq Ahmad, Chaudhary Bakhtawar Khan, Raja Khawar Nawaz
School of Pharmacy, The University Of Lahore, (Islamabad Campus), Islamabad, Pakistan
Keywords: Diabetes, retinopathy, cardiopathy, stroke, hypertension.
Abstract

Prognosis of uncontrolled Diabetes Mellitus (DM) is a major reason of secondary complications. Which are eventually increasing the morbidities and mortalities in all over the world. The correct dose and protocols most probably reduce the chances of secondary complications. Therefore; we have aimed this case report to rationalize the anti-hyperglycemic drugs. A 51 years old woman with frequent chest pain, headache, neckache, sweating and radiating pain in left arm was presented in clinical setup. She has diabetes since the last 10 years and hypertensive since 5 years. Initially she tried to manage her disease by controlling her diet and then started Tab. Glucophage (Metformin) 250 mg in morning, 500 mg at bed time and Herbesser Tablet (Diltiazem) as antihypertensive agent. Afte some time her medications were changed; Tab Lowplat (Clopidogrel) Tab. Ulcenil, Tab Disprin CV 300 mg, Tab Herbesser 30 mg tid, Tab Nitromint, tab Vastarel MR bid and Atorvastatin 20 mg for 4 weeks. After 6 months, angioplastic report showed the same results. She was admitted again in same hospital for clinical support of her uncontrolled glucose, fluctuating blood pressure and development of secondary complications. It is thus inferred from this case report that the aggressive and irrational medications may develop the secondary complications. The patient with family history of diabetes and hypertension need more care. Thus it is understood that hypertension and diabetes should be treated seriously to avoid the complications.

Article Information

Identifiers and Pagination:
Year:2011
Volume:3
First Page:20
Last Page:23
Publisher Id:JAppPharm (2011 ). 3. 20-23
Article History:
Received:October 17, 2010
Accepted:December 21, 2010
Collection year:2010
First Published:January 11, 2011


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
doi: http://dx.doi.org/10.21065/19204159
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/